Search research articles
Contact Us
Filters
Showing results (41-50 of 50) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 50 results.
Nature Medicine
|
July 24, 2019
GM-CSF and CXCR4 define a T helper cell signature in multiple sclerosis
Edoardo Galli, Felix J Hartmann, Bettina Schreiner, et al.
Cancer Research
|
June 21, 2020
IL6 Fuels Durable Memory for Th17 Cell-Mediated Responses to Tumors
Hannah M Knochelmann, Connor J Dwyer, Aubrey S Smith, et al.
Cell Reports
|
December 24, 2013
Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein-Barr virus infection
Obinna Chijioke, Anne Müller, Regina Feederle, et al.
Journal for Immunotherapy of Cancer
|
June 15, 2025
Multiomics identifies tumor-intrinsic SREBP1 driving immune exclusion in hepatocellular carcinoma
Rebekah E Dadey, Ruxuan Li, Jake Griner, et al.
Science Translational Medicine
|
January 10, 2020
Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-β
Alessandra Metelli, Bill X Wu, Brian Riesenberg, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
March 1, 2022
Phase I Trial Characterizing the Pharmacokinetic Profile of N-803, a Chimeric IL-15 Superagonist, in Healthy Volunteers
Mark P Rubinstein, Cameron Williams, Caroline Mart, et al.
Science Advances
|
July 20, 2022
Noncanonical activation of GLI signaling in SOX2<sup>+</sup> cells drives medulloblastoma relapse
Marzena Swiderska-Syn, Júlia Mir-Pedrol, Alexander Oles, et al.
Cell Reports. Medicine
|
November 10, 2021
Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma
Sixue Liu, Hannah M Knochelmann, Shirley H Lomeli, et al.
The Lancet. Oncology
|
April 10, 2018
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
John M Wrangle, Vamsidhar Velcheti, Manish R Patel, et al.
The Journal of Clinical Investigation
|
October 12, 2023
Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1
Callum Beach, David MacLean, Dominika Majorova, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 50) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 50 results.
Nature Medicine
|
July 24, 2019
GM-CSF and CXCR4 define a T helper cell signature in multiple sclerosis
Edoardo Galli, Felix J Hartmann, Bettina Schreiner, et al.
Cancer Research
|
June 21, 2020
IL6 Fuels Durable Memory for Th17 Cell-Mediated Responses to Tumors
Hannah M Knochelmann, Connor J Dwyer, Aubrey S Smith, et al.
Cell Reports
|
December 24, 2013
Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein-Barr virus infection
Obinna Chijioke, Anne Müller, Regina Feederle, et al.
Journal for Immunotherapy of Cancer
|
June 15, 2025
Multiomics identifies tumor-intrinsic SREBP1 driving immune exclusion in hepatocellular carcinoma
Rebekah E Dadey, Ruxuan Li, Jake Griner, et al.
Science Translational Medicine
|
January 10, 2020
Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-β
Alessandra Metelli, Bill X Wu, Brian Riesenberg, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
March 1, 2022
Phase I Trial Characterizing the Pharmacokinetic Profile of N-803, a Chimeric IL-15 Superagonist, in Healthy Volunteers
Mark P Rubinstein, Cameron Williams, Caroline Mart, et al.
Science Advances
|
July 20, 2022
Noncanonical activation of GLI signaling in SOX2<sup>+</sup> cells drives medulloblastoma relapse
Marzena Swiderska-Syn, Júlia Mir-Pedrol, Alexander Oles, et al.
Cell Reports. Medicine
|
November 10, 2021
Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma
Sixue Liu, Hannah M Knochelmann, Shirley H Lomeli, et al.
The Lancet. Oncology
|
April 10, 2018
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
John M Wrangle, Vamsidhar Velcheti, Manish R Patel, et al.
The Journal of Clinical Investigation
|
October 12, 2023
Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1
Callum Beach, David MacLean, Dominika Majorova, et al.
Page
of 5